Nov 24, 2022 09:04 JST

Source: Eisai

Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

TOKYO, Nov 24, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be held in Nashville, Tennessee and virtually from December 2-6, 2022.

Key data Presentations for perampanel include the:
- Results from a post hoc analysis of the phase III clinical trial (FREEDOM/342), which evaluated long-term efficacy of perampanel monotherapy by seizure type in the open-label extension (52 weeks) for epilepsy patients with focal-onset seizures (FOS), ≥ 12 years of age without prior treatment history (poster number: 2.228)
- Real-world pooled analyses of perampanel for pediatric patients (poster number: 1.310),
adolescent patients (poster number: 1.313) and elderly patients (poster number: 1.312)
- Results from a post hoc analysis of two phase III open-label extension (OLEx) studies, Study 307 and Study 335 OLEx, evaluating the long-term efficacy and safety of adjunctive perampanel in a subgroup of older adult patients aged ≥ 60 years (poster number: 1.291)

"With 34 poster presentations planned for this year's AES Meeting, we look forward to furthering our understanding of the results that may impact overall care in epilepsy," said Ivan Cheung, Senior Vice President Global Alzheimer's Disease Officer President, Americas Region, Eisai Co., Ltd., "We remain focused on addressing the diverse needs of patients with epilepsy and their families."

Perampanel is a first-in-class AED discovered by Eisai's Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper- excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. The agent is currently approved for partial-onset seizures (with or without secondarily generalized seizures) in over 70 countries including Japan, the United States, China and other countries in Europe and in Asia. The agent is currently approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 70 countries including Japan, the United States, and other countries in Europe and in Asia.

Eisai considers neurology, including epilepsy, a therapeutic area of focus. Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy. Eisai remains committed further to addressing the diverse needs of, and increasing the benefits provided to, patients with epilepsy and their families

For more information, visit www.eisai.com/news/2022/pdf/enews202281pdf.pdf.

Source: Eisai
Sectors: BioTech

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
March 24 2023 12:22 JST
 
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
March 23 2023 12:30 JST
 
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal
March 20 2023 10:18 JST
 
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease
March 14 2023 10:09 JST
 
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award
March 10 2023 14:04 JST
 
Eisai Certified as a 2023 Health and Productivity Management Outstanding
March 09 2023 08:07 JST
 
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
March 06 2023 09:58 JST
 
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan
March 02 2023 09:45 JST
 
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 28 2023 14:28 JST
 
Dissolution of Bracco-Eisai Joint Venture
February 21 2023 13:02 JST
 
More Press release >>

Latest Press Release


More Latest Release >>